Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable‐risk prostate cancer: A secondary analysis of a randomized clinical trial
This study validates that a PSA level >0.5 ng/mL after neoadjuvant androgen deprivation therapy and before RT is prognostic and significantly associated with an increased ACM risk. Patients achieving this endpoint should be considered for enrollment in future randomized trials evaluating the impact of treatment escalation on ACM using a prerandomization stratification by age or validated comorbidity metrics.
Authors
- Mutlay Sayan (ORCID: https://orcid.org/0000-0002-0101-0951)
- Paul Linh Nguyen (ORCID: https://orcid.org/0000-0003-4268-3973)
- Jonathan E. Leeman (ORCID: https://orcid.org/0000-0003-4539-0762)
- Martin T. King (ORCID: https://orcid.org/0000-0002-4097-5107)
- Peter F. Orio (ORCID: https://orcid.org/0000-0002-0594-4727)
- Shalini Moningi (ORCID: https://orcid.org/0000-0003-2638-8202)
- Ming‐Hui Chen (ORCID: https://orcid.org/0000-0003-1935-2447)
- Jing Wu (ORCID: https://orcid.org/0000-0003-3615-4581)
- Anthony V. D’Amico
Institutions
- Brigham and Women's Hospital (US)
- University of Connecticut (US)
- University of Rhode Island (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1002/cncr.35674
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.42